NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Zentalis reported third quarter results, highlighted by clinical progress of ZN-c5 and ZN-c3, a clinical collaboration with Eli Lilly, and a follow-on offering.
Zentalis Pharmaceuticals reported a net loss of $34.7 million for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $367.4 million as of September 30, 2020. The company made progress in its oncology pipeline, including ZN-c5 and ZN-c3, and entered a collaboration with Eli Lilly.
- Announced topline data from the Phase 1 monotherapy dose escalation trial of ZN-c5, its investigational oral SERD, in patients with ER+/HER2- advanced breast cancer.
- Entered into a clinical collaboration with Eli Lilly to evaluate ZN-c5 in combination with abemaciclib, a CDK4 and 6 inhibitor.
- Raised an additional ~$166.0 million in gross proceeds from recent follow-on offering.
- Preparing to initiate the Phase 2 trial in patients with ER+/HER2- advanced breast cancer in the first half of 2021.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$400K
Forward guidance
Zentalis expects that its existing cash, cash equivalents and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements into 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2020
-1.4%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+0.8%
Avg return
30 days after
60%
15 / 25 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +3.1% | -3.2% | — | |
| Q1 2026 | +3.9% | -1.7% | -15.0% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q2 2025 | +5.1% | +2.2% | +26.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro